Effect of EA Combined With NGF on Limb Function in Convalescent Patients With Ischemic Stroke

Inclusion Criteria: * people with first-ever ischemic stroke confirmed by CT or/and MRI; * 14 days to 6 months after stroke onset; * 50 years≤aged≤80 years; * 3≤modified Rankin Score (mRS)≤4; * Patients can accept treatment with EA and have good compliance; * Patients have clear consciousness, pain perception and resolution ability to complete basic communication; * willing to participate and be randomized to one of the groups. Exclusion Criteria: * transient ischemic attack, subarachnoid hemorrhage, cerebral hemorrhage and other cerebrovascular diseases; * severe heart, liver, kidney dysfunction and severe coagulation dysfunction; cerebral infarction caused by repeated recurrence of stroke, brain surgery or trauma, and brain tumors; * severe neurological deficits before stroke, such as visual and auditory impairment, aphasia, agnosia, severe hemiplegia, or affected limb function before stroke, such as cerebral palsy, polio, fracture, and mRs≥1; * diseases with affecting cognitive function such as congenital dementia, or alcohol, drug or substance abuse ; * lactation, pregnancy or intend to be pregnant within 6 months; * needlesickness, needle phobia and skin infection at acupuncture site; * pacemaker, implantable cardioverter defibrillator carriers or conductive metallic foreign bodies in the body; * allergy to NGF; * currently enrolled in another clinical trial or participation in other clinical trials within the last 3 months.